Key Takeaways
- Valuation is no longer driven by science alone.
- Commercial readiness can strengthen partnership, financing and acquisition optionality.
- Weak commercial assumptions create valuation risk even when clinical data are strong.
- Boards should connect commercial strategy to enterprise narrative early.
Twenty years ago, biotechnology valuations were driven primarily by scientific innovation and clinical results.
Today, investors ask a broader question: can this therapy succeed commercially?
That shift means commercial strategy influences enterprise value long before the first prescription. Related perspective: choosing the right commercial direction.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
